Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 61Neoplasm Metastasis 6Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasms by Site 2Melanoma 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Breast Diseases 2Anatomic Stage II Breast Cancer AJCC v8 2Venous Thromboembolism 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Meningioma 1

Interventions

Letrozole 2trametinib 1ribociclib 1niraparib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cystadenocarcinoma, Serous × ribociclib × 1 year × Clear all
NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled 19 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡